Angiotensin converting enzyme inhibitors or angiotensin II receptor blocker in cardiovascular and renal pathology in 2006: What does EBM teach us?;Inhibiteurs de l'enzyme de conversion de l'angiotensine ou antagonistes des récepteurs de l'angiotensine 2 en pathologie cardio-vasculaire et néphrologique: Que nous dit l'evidence based medicine?

Revue Medicale de Liege

Volumn 61, Issue 5-6, 2006, Pages 414-422

  Krzesinski, J M ^a   Montrieux, Ch ^b   Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b U L B

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II receptor blocker; Cardiovascular disease; Evidence based medicine; Renal disease

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BELSAR; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIOVANE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE; EPROSARTAN; IRBESARTAN; LISINOPRIL; LOORTAN; LOSARTAN POTASSIUM; OLMESARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY PREVENTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY DISEASES; RECEPTOR, ANGIOTENSIN, TYPE 2;

EID: 33745921218     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003, 21, 1011-1058.
2. Dahlöf B, Devereux R, Kjeldsen S, et al.- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 995-1003.
3. Pitt B, Segal R, Martinez F, et al.- Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet, 1997, 349, 747-752.
4. Pitt B, Poole-Wilson PA, Segal R, et al.- The effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The losartan heart failure survival study, ELITEII). Lancet, 2000, 355, 1582-1587.
5. Cohn J, Tognoni G, for the Valsartan Heart Failure Trial Investigators.- A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2004, 345, 1667-1675.
6. Pfeffer M, Swedberg K, Granger C, et al.- Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet, 2003, 362, 759-766.
7. Granger C, McMurray J, Yusuf S, et al.- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet, 2003, 362, 772-776.
8. McMurray J, Östergen J, Swedberg K, et al.- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet, 2003, 362, 767-771.
9. Yusuf S, Pleffer M, Swedberg K, et al.- Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet, 2003, 362, 777-781.
10. Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).- ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am CollCardiol, 2005, 46, 1-82.
11. Swedberg K, Cleland J, Dargie H, et al. The task force for the diagnosis and treatment of CHF of the European Society of Cardiology.- Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). Eur Heart J, 2005, 26, 1115-1140.
12. Dickstein K, Kjekshus J, and the OPTIMAAL steering committee, for the OPTIMAAL study group.- Effects of losartan and captopril on mortality and morbidity in high-risk patients with acute myocardial infarction: the OPTIMAAL randomised trial. Lancet, 2002, 360, 752-760.
13. Pfeffer M, McMurray J, Velázques E, et al.- Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 2003, 349, 1893-1906.
14. Antman EM, Anbe DT, Armstrong PW, et al.- ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol, 2004, 44, E1-E211.
15. Krzesinski J-M.- L'hyperkaliÉmie, ce nouveau tueur? Rev Med Liège, 2005, 60, 222-226.
16. Hansson L, Lindholm LH, Niskanen L, et al.- Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet, 1999, 353, 611-616.
17. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA, 2002, 288, 2981-2997.
18. Wing L, Reid C, Ryan P, et al.- A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med, 2003, 348, 583-592.
19. The Heart Outcome Prevention Evaluation Study Investigators.- Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med, 2000, 342, 145-153.
20. PROGRESS collaborative group.- Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet, 2003, 358, 1033-1041.
21. Schrader J, Lüders S, Kulschewski A, et al.- The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke, 2003, 34, 1699-1703.
22. Schrader J, Lüders S, Kulschewski A, et al.- Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke, 2005, 36, 1218-1226.
23. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.- Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003, 362, 782-788.
24. Yusuf S, Pogue J.- ACE inhibition in stable coronary artery disease. N Engl J Med, 2005, 352, 937-939.
25. Lewis E, Hunsicker L, Bain R, et al.- The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. N Engl J Med, 1993, 329, 1456-1462.
26. Maschio G, Alberti D, Janin G, et al.- Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency (AIPRI). N Engl J Med, 1996, 334, 939-945.
27. Barnett A, Bain S, Bouter P, et al.- Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med, 2004, 351, 1952-1961.
28. Brenner B, Cooper M, De Zeeuw D, et al.- Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001, 345, 861-869.
29. Parving HH, Lehnert H, Bröchner-Mortensen J, et al.- The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 2001, 345, 870-878.
30. Lewis E, Hunsicker L, Clarke W, et al.- Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001, 345, 851-860.
31. Viberti G, Wheeldon NM, MicroAlbuminuria Reduction with VALsartan (MARVAL) study investigators.- Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation, 2002, 106, 672-678.
32. Nakao N, Yoshimura A, Morita H, et al.- Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet, 2003, 361, 114-124.
33. Ruggenenti P, Fassi A, Parvanovo A, et al.- Preventive microalbuminuria in type 2 diabetes. N Engl J Med, 2004, 351, 1941-1951.
34. Mogensen C, Neldam S, Tikkanen I, et al.- Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321, 1440-1444.
35. Scheen AJ.- Réduction comparable des nouveaux cas de diabète de type 2 sous sartan et sous inhibiteur de l'enzyme de conversion de l'angiotensine: comparaison des méta-analyses des essais prospectifs randomisés. Rev Med Liège, 2005, 60, 424-428.